Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TTC9 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
mRNA | PRKCB | CTRPv2 | pan-cancer | AAC | -0.099 | 0.01 |
mRNA | RP11-345F18.1 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
mRNA | HDC | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
mRNA | PCDHA11 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
mRNA | MBOAT7 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
mRNA | SLA2 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
mRNA | RP5-1052I5.2 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
mRNA | KLHL31 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
mRNA | IFNL1 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |